To read the full story, subscribe or sign in.

FDA grants priority review to Seattle Genetics' brentuximab vedotin BLAs

May 4, 2011

BioWorld Science Cancer

Today's news in brief

BioWorld

BioWorld briefs for May 4, 2026.

News in brief

BioWorld Asia

BioWorld Asia briefs for May 5, 2026

Axsome’s Auvelity cleared for large Alzheimer’s agitation market

BioWorld

Axsome Therapeutics Inc. won U.S. FDA approval for Auvelity (AXS-05) to treat Alzheimer’s disease agitation, a condition that affects up to three-quarters of...

Sonire starts US study of cancer HIFU after $18M series A

BioWorld

Sonire Therapeutics Inc. initiated a U.S.-based Sunrise II study of Suizenji, its novel ultrasound-guided high-intensity focused ultrasound (HIFU) system designed...

How to Summit up? Dis-Harmoni on ivonescimab NSCLC phase III

BioWorld

Wall Street pundits were divided about the likely fate of ivonescimab, Summit Therapeutics Inc.’s bispecific antibody partnered with Akeso Pharmaceuticals Inc.,...